Michael Earl from Owen Mumford considers the benefits of connectivity and how this can be best utilised by pharma companies
Betsy Goodfellow and James Spargo from Pharmafocus explore the investigation around contaminated cough syrups following a timeline that includes products manufactured by Maiden Pharmaceuticals, Marion Biotech and other companies
Page 4 – Sanofi to cut insulin prices by 78% starting January 2024
Page 6 – AstraZeneca reports positive results of drug combination in
late-stage ovarian cancer trial
Page 7 – Promising ovarian cancer drug enters phase 3 trial
Page 8 – AstraZeneca’s Lynparza approved by NHS England
Page 9 – NeuroRPM announces FDA clearance for AI monitoring app for Parkinson’s disease on Apple Watch
Executive Director
PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow
betsy@pharmafile.com
James Spargo
james@samedanltd.com
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2023 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.